Where can I buy shares of OPK?
Shares of OPK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Will OPKO Health stock trade lower or higher?
The rapid run-up in its shares prompted Hindenburg Research, a short-seller that's been bearish on OPKO Health since 2018, to reassert its belief that it will trade significantly lower, not higher. Image source: Getty Images.
Will PPF buy out OPK?
PFE may just buy out OPK which is what they normally due with their follow partners. 01/12/21 (Reuters) – Quest Diagnostics said on Wednesday it was performing more than 100,000 COVID-19 tests a day, as the Omicron coronavirus variant drives a surge in testing demand in the United States.
What are the earnings earnings for OPKO Health (OPK)?
OPKO Health, Inc. (NASDAQ:OPK) released its earnings results on Thursday, October, 28th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.01) by $0.05.
See more
Is OPK stock a good buy?
Out of 3 analysts, 2 (66.67%) are recommending OPK as a Strong Buy, 0 (0%) are recommending OPK as a Buy, 1 (33.33%) are recommending OPK as a Hold, 0 (0%) are recommending OPK as a Sell, and 0 (0%) are recommending OPK as a Strong Sell.
Is OPK undervalued?
BLUF: OPK is extremely undervalued, profitable, growing revenue, its star pipeline drug approaching BLA submission, and has a very promising COVID treatment under trial.
Does opko health pay dividends?
OPKO Health, Inc. has not declared or paid cash dividends. The company has retained earnings for the operation and expansion of its business and does not anticipate paying any cash dividends in the foreseeable future.
Does OPK stock pay dividends?
OPK does not currently pay a dividend.
What does opko Health do?
OPKO Health is a medical test and medication company focused on diagnostics and pharmaceuticals. The company is a publicly traded company on NASDAQ and TASE under the symbol "OPK".
Where can I buy OPK stock?
Shares of OPK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
OPKO Health Q1 Earnings Match Estimates, Revenues Top
Revenue Details
OPKO Health, Inc. reported first-quarter 2021 adjusted earnings per share of 5 cents per share, which met the Zacks Consensus Estimate. Notably, the company had reported a loss of 9 cents in the prior-year quarter.
Segmental Revenues in Q1
First-quarter revenues of the company were $545.2 million, which surpassed the Zacks Consensus Estimate by 8.4%. The top line also improved 157.8% on a year-over-year basis.
Margin Analysis
Revenues from Services amounted to $507 million in the reported quarter, up 196.8% year over year driven by COVID-19 testing volume.
When will OPKO Health release its earnings?
Gross profit in the reported quarter was $181.7 million, up 155.2% from the prior-year quarter. Gross margin was 33.3% of net revenues, down 40 basis points (bps) year over year. Selling, general and administrative expenses totaled $112.3 million, up 47.6% year over year.
How much does Opko Health make?
OPKO Health is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021. View our earnings forecast for OPKO Health.
OPKO Health (OPK) Gains As Market Dips: What You Should Know
OPKO Health has a market capitalization of $2.36 billion and generates $1.44 billion in revenue each year. The biotechnology company earns $30.59 million in net income (profit) each year or $0.05 on an earnings per share basis.
7 Insider Stocks to Buy as Execs Snap Them Up
In the latest trading session, OPKO Health (OPK) closed at $3.15, marking a +0.32% move from the previous day.
Pfizer (PFE) Gets EU Nod for Somatrogon & Pneumococcal Jab
With so much information proliferating the internet about equity market opportunities, it’s hard to know whom to trust. That’s especially the case when you consider insider stocks or transactions that corporate insiders — executives, high-level employees and major stakeholders — execute on the companies with which they are associated.
OPKO's (OPK) NGENLA to Offer GHD Treatment in European Union
Pfizer (PFE) gets approval for pediatric growth hormone deficiency drug, Ngenla (somatrogon) and 20-valent pneumococcal conjugate vaccine, Apexxnar, in Europe.
OPKO Health (OPK) to Post Q4 Earnings: What's in the Cards?
OPKO's (OPK) marketing authorization for NGENLA in the European Union stands to benefit children and adolescents affected by growth hormone deficiency.
Analysts Estimate OPKO Health (OPK) to Report a Decline in Earnings: What to Look Out for
OPKO Health's (OPK) fourth-quarter results are likely to reflect strength in Rayaldee.
Quotient (QTNT) Reports Q3 Loss, Tops Revenue Estimates
OPKO Health (OPK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What is OPK in healthcare?
Quotient (QTNT) delivered earnings and revenue surprises of -76% and 10.57%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Who is OPK testing?
OPKO Health, Inc. (NASDAQ:OPK) a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. Their CEO has been continuously buying shares, and we were curious as to why that might be. Motley Fool • 15 days ago.
Who is OPK in 2021?
BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced a COVID-19 testing program for U.S. based crew and guests who cruise with Royal Caribbean Group, helping provide a safe environment for travelers.
Is Opko Health a bearish company?
MIAMI, June 17, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces that its subsidiary, EirGen Pharma, Ltd., has entered into a definitive agreement to sell one of its facilities in Waterford, Ireland to Horizon Therapeutics plc (Nasdaq: HZNP) for $65 million in cash less certain assumed and accrued liabilities relating to transferred employees. The facility houses EirGen’s sterile-fill-finish business. EirGen’s research and development employees who were located at the site will
Is Opko Health burning through cash?
The rapid run-up in its shares prompted Hindenburg Research, a short-seller that's been bearish on OPKO Health since 2018, to reassert its belief that it will trade significantly lower, not higher.
Why do companies issue convertible notes?
There's no question that OPKO Health is burning through cash. In 2019, the healthcare company reported a $315 million net loss on revenue of $224 million. As a result, OPKO's cash balance slipped to $85.5 million from $96.5 million exiting 2018, despite raising $81.3 million via an underwritten public stock offering in Q4.
Will Opko's convertible notes go away?
Companies issue convertible senior notes all the time to raise money without the transactions taking a significant toll on their stock prices. The problem for Opko Health came from its move to issue a large number of new shares in connection with its notes offering.
A minor clinical trial success has been followed by a big share offering
All of the problems created by Opko offering convertible senior notes and issuing new shares in connection with the move will go away if the company achieves strong growth that drives its share price up. However, the prospect s for that happening don't seem to be very good right now.
What happened
Cory is a long-term minded analyst focused on the Healthcare Sector. He genuinely enjoys cutting through the complexity to help everyday investors make better decisions. Follow @coryrenauer
So what
Shares of OPKO Health ( NASDAQ:OPK) , a diagnostics and biopharmaceutical company, fell hard today after the company announced a secondary share offering. Investors unhappy about dilution of the value of their shares pushed the stock 14.2% lower on Thursday.
Now what
After losing $141 million in the first half of 2019, the company finished June with $111 million in cash on its balance sheet and $68 million of high-interest debt that's due in 2020. That leaves it without a lot of options at the moment.
What happened
OPKO announced its impending share offering shortly after announcing success in a non-inferiority test with somatrogon, a once-weekly growth hormone injection for children who don't produce enough on their own. The current standard, Genotropin from Pfizer ( NYSE:PFE), is just as effective, but parents need to inject their children every day.
So what
After reporting a year-over-year decline in revenue that was worse than industry watchers expected, OPKO Health ( OPK -3.17% ) saw its shares fall 16.7% on Thursday.
NASDAQ: OPK
Although the healthcare company is benefiting from significant demand for COVID-19 tests, rising demand in the final weeks of the first quarter wasn't enough to offset declining demand for lab services caused by widespread shelter-in-place orders that reduced visits to primary- and specialty-care doctors.
Now what
The company's net loss per share was $0.09 on a GAAP basis, which was in line with analyst forecasts. Its $59.1 million net loss was an improvement from an $80.8 million net loss last year.
Premium Investing Services
OPKO Health began providing testing for the SARS-CoV-2 coronavirus in various states, including New York, on March 13. Initially, volume was limited because of testing constraints, but volume has expanded significantly over the past month.
Business
Risks
- 2 equities research analysts have issued 1-year target prices for Opko Health's stock. Their predictions range from $5.00 to $20.00. On average, they anticipate Opko Health's share price to reach $12.50 in the next year. This suggests a possible upside of 489.6% from the stock's current price. View Analyst Price Targets for Opko Health.
Ratings
- 2 Wall Street analysts have issued \"buy,\" \"hold,\" and \"sell\" ratings for Opko Health in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of \"Buy.\" View Analyst Ratings for Opko Health.
Reception
- Headlines about OPK stock have trended neutral this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Opko Health e…
Ownership
- Opko Health's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.90%), Dimensional Fund Advisors LP (0.70%), Wells Fargo & Company MN (0.24%), RK Asset Management LLC (0.19%), Fosun International Ltd (0.14%) and Pictet Asset Management Ltd. (0.11%). Company insiders that own Opko Health stock include A…
Operations
- Opko Health has a market capitalization of $1.31 billion and generates $990.30 million in revenue each year. The biotechnology company earns $-153,040,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis. Opko Health employs 5,690 workers across the globe.
Access
- Opko Health's mailing address is 4400 BISCAYNE BLVD., MIAMI FL, 33137. The biotechnology company can be reached via phone at 305-575-4100 or via email at [email protected].